Aridis Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OTC.Pink
Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 11.43% of Aridis Pharmaceuticals, Inc. common stock as of June 30, 2026.
OTC.Pink
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 11.43% in Aridis Pharmaceuticals, Inc. common stock as of March 31, 2026.
OTC.Pink
Armistice Capital and Steven Boyd report a continued 11.43% beneficial ownership stake in Aridis Pharmaceuticals, Inc. common stock.